Brainstorm Cell Therapeutics Submits Special Protocol Assessment (Spa) Request To Fda For Phase 3B Trial Of Nurown In Amyotrophic Lateral Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Brainstorm Cell Therapeutics has submitted a Special Protocol Assessment (SPA) request to the FDA for a Phase 3B trial of NurOwn in Amyotrophic Lateral Sclerosis (ALS). This step is crucial for advancing the treatment's development and potentially bringing it closer to market approval.
February 23, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Brainstorm Cell Therapeutics' submission of an SPA request to the FDA for a Phase 3B trial of NurOwn in ALS represents a significant development milestone. This could positively influence investor sentiment and the company's valuation if the market perceives it as a step closer to potential FDA approval.
Submitting an SPA request to the FDA is a critical regulatory step for Brainstorm Cell Therapeutics, indicating progress in the development of NurOwn for ALS. This move could be seen as a positive indicator of the company's commitment to advancing its treatment, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100